Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Kulke · SciRah

Researcher profile · Semantic Scholar

M. Kulke

Share profile

M. Kulke — researcher profile on SciRah

h-index: 80
Works: 381
Citations: 25K

Most-cited papers

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Antonino Glaviano, A. S. Foo, Hiu Y. Lam, K. C. Yap +23 more
2023Molecular Cancer2,000 citations Open access
Semantic Scholar
Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.
M. Yurgelun, M. Kulke, C. Fuchs, Brian A. Allen +14 more
2017Journal of Clinical Oncology448 citations Open access
Semantic Scholar
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial.
J. Strosberg, E. Wolin, B. Chasen, M. Kulke +12 more
2018Journal of Clinical Oncology327 citations Open access
Semantic Scholar
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
T. Hope, E. Bergsland, M. Bozkurt, Michael M. Graham +13 more
2018Journal of Nuclear Medicine325 citations Open access
Semantic Scholar
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.
M. Shah, W. Goldner, T. Halfdanarson, E. Bergsland +32 more
2018The Journal of the National Comprehensive Cancer Network320 citations Open access
Semantic Scholar
Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine
Andrew J. Aguirre, J. Nowak, Nicholas D. Camarda, R. Moffitt +57 more
2018Cancer Discovery306 citations Open access
Semantic Scholar
Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer
A. Klein, B. Wolpin, H. Risch, R. Stolzenberg-Solomon +119 more
2018Nature Communications233 citations Open access
Semantic Scholar
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)
P. Kunz, N. Graham, P. Catalano, H. Nimeiri +15 more
2022Journal of Clinical Oncology180 citations Open access
Semantic Scholar
Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors
P. Cejas, Y. Drier, K. Dreijerink, L. Brosens +23 more
2019Nature Medicine157 citations Open access
Semantic Scholar
Altered exocrine function can drive adipose wasting in early pancreatic cancer
Laura V. Danai, A. Babic, M. Rosenthal, Emily A. Dennstedt +25 more
2018Nature132 citations Open access
Semantic Scholar
Phase 3 Trial of Cabozantinib in Advanced Neuroendocrine Tumors
Jennifer A. Chan, Susan M. Geyer, T. Zemla, Michael V. Knopp +20 more
2024New England Journal of Medicine120 citations Open access
Semantic Scholar
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial
M. Pavel, D. Gross, M. Benavent, P. Perros +14 more
2018Endocrine-Related Cancer119 citations Open access
Semantic Scholar
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study
J. Strosberg, P. Kunz, A. Hendifar, James C. Yao +42 more
2020European Journal of Nuclear Medicine and Molecular Imaging110 citations Open access
Semantic Scholar
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial
M. Kulke, P. Ruszniewski, E. Van Cutsem, C. Lombard-Bohas +14 more
2017Annals of Oncology99 citations Open access
Semantic Scholar
Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET).
J. Chan, J. Faris, J. Murphy, L. Blaszkowsky +13 more
201791 citations
Semantic Scholar
Characterization of the Neuroendocrine Tumor Immune Microenvironment
Annacarolina F. L. Da Silva, M. Bowden, Sui Zhang, Y. Masugi +9 more
2018Pancreas77 citations Open access
Semantic Scholar
Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
M. Pavel, S. Singh, J. Strosberg, L. Bubuteishvili-Pacaud +20 more
2017The Lancet Oncology64 citations Open access
Semantic Scholar
Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib
N. Fazio, M. Kulke, B. Rosbrook, Kathrine C. Fernandez +1 more
2021Targeted oncology58 citations Open access
Semantic Scholar
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours
E. Raymond, M. Kulke, S. Qin, Xianjun Yu +26 more
2018Neuroendocrinology48 citations Open access
Semantic Scholar
Plasma inflammatory cytokines and survival of pancreatic cancer patients
A. Babic, N. Schnure, Neermala Poudel Neupane, M. Zaman +14 more
2018Clinical and Translational Gastroenterology47 citations Open access
Semantic Scholar
Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary
S. Singh, C. Carnaghi, R. Buzzoni, R. Pommier +16 more
2017Neuroendocrinology47 citations Open access
Semantic Scholar
Post diagnosis loss of skeletal muscle, but not adipose tissue, is associated with shorter survival of patients with advanced pancreatic cancer
A. Babic, M. Rosenthal, W. Bamlet, N. Takahashi +20 more
2019Cancer Epidemiology, Biomarkers and Prevention40 citations Open access
Semantic Scholar
Enhanced detection of microsatellite instability using pre-PCR elimination of wild-type DNA homo-polymers in tissue and liquid biopsies
I. Ladas, F. Yu, K. Leong, Mariana Fitarelli-Kiehl +5 more
2018Nucleic Acids Research38 citations Open access
Semantic Scholar
Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials.
James C. Yao, A. Garg, David J. Chen, J. Capdevila +12 more
2019Endocrine-Related Cancer34 citations Open access
Semantic Scholar
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response
A. Lamarca, J. Barriuso, M. Kulke, I. Borbath +8 more
2017British Journal of Cancer31 citations Open access
Semantic Scholar
Intertumoral lineage diversity and immunosuppressive transcriptional programs in well-differentiated gastroenteropancreatic neuroendocrine tumors
Samantha E. Hoffman, Todd W. Dowrey, Carlos Villacorta Martin, Kevin Bi +31 more
2022bioRxiv30 citations Open access
Semantic Scholar
Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions
Harshabad Singh, Yvonne Y. Li, L. Spurr, A. Shinagare +26 more
2021Clinical Cancer Research29 citations Open access
Semantic Scholar
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE
J. Strosberg, R. Srirajaskanthan, G. El-Haddad, E. Wolin +12 more
2021Journal of Nuclear Medicine27 citations Open access
Semantic Scholar
Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR.
D. Cella, J. Beaumont, S. Hudgens, F. Marteau +7 more
2018Clinical Therapeutics27 citations Open access
Semantic Scholar
First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.
J. Strosberg, E. Wolin, B. Chasen, M. Kulke +9 more
201827 citations
Semantic Scholar
LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)
J. Chan, S. Geyer, F. Ou, M. Knopp +15 more
2023Annals of Oncology25 citations
Semantic Scholar
Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.
M. Weickert, G. Kaltsas, D. Hörsch, P. Lapuerta +14 more
2018Clinical Therapeutics24 citations Open access
Semantic Scholar
Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division
A. Abbott, C. Sakellis, Eric Andersen, Yuji Kuzuhara +6 more
2018Journal of Nuclear Medicine Technology24 citations Open access
Semantic Scholar
Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms
E. Baudin, A. Hayes, J. Scoazec, P. Filosso +13 more
2018Neuroendocrinology24 citations Open access
Semantic Scholar
First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results.
M. Johnson, T. Meyer, D. Halperin, A. Fojo +11 more
201820 citations
Semantic Scholar
Development of a Framework Based on Reflective MCDA to Support Patient–Clinician Shared Decision-Making: The Case of the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the United States
Monika Wagner, D. Samaha, H. Khoury, William M. O’Neil +8 more
2017Advances in Therapy20 citations Open access
Semantic Scholar
Cancer stage at presentation for incarcerated patients at a single urban tertiary care center
Kathryn I. Sunthankar, Kevin N. Griffith, Stephanie D. Talutis, Amy K. Rosen +4 more
2020PLoS ONE19 citations Open access
Semantic Scholar
Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma.
Laura Burns, H. Tukachinsky, K. Raskina, R. Huang +5 more
2023Lung Cancer18 citations Open access
Semantic Scholar
Retrospective review of serotonergic medication tolerability in patients with neuroendocrine tumors with biochemically proven carcinoid syndrome
Diana D. Shi, David P. Yuppa, Trevor Dutton, L. Brais +5 more
2017Cancer18 citations Open access
Semantic Scholar
Reply to ‘H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines’
Mariano J. Alvarez, P. Yan, M. Alpaugh, M. Bowden +17 more
2019Nature Genetics15 citations Open access
Semantic Scholar
Everolimus With or Without Bevacizumab in Advanced pNET: CALGB 80701 (Alliance)
M. Kulke, F. Ou, Donna Niedzwiecki Ph D, Lucas Heubner +7 more
2022Endocrine-Related Cancer14 citations Open access
Semantic Scholar
Clinical Implications of Pathogenic Germline Variants in Small Intestine Neuroendocrine Tumors (SI-NETs)
K. Perez, M. Kulke, A. Chittenden, C. Ukaegbu +13 more
2021JCO Precision Oncology14 citations
Semantic Scholar
Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.
A. Dasari, E. Bergsland, A. Benson, B. Cai +10 more
2019The Oncologist14 citations Open access
Semantic Scholar
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.
M. Kulke, P. Ruszniewski, E. Van Cutsem, C. Lombard-Bohas +14 more
2019Annals of Oncology14 citations Open access
Semantic Scholar
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.
Kimberly Perez, H. Jacene, J. Hornick, Chao Ma +10 more
2022Endocrine-Related Cancer13 citations
Semantic Scholar
Insulin-like growth factor-1 receptor expression and disease recurrence and survival in patients with resected pancreatic ductal adenocarcinoma
C. Du, Annacarolina F. L. Da Silva, V. Morales-Oyarvide, A. D. Costa +24 more
2020Cancer Epidemiology, Biomarkers and Prevention13 citations Open access
Semantic Scholar
Predictors of Recurrence and Survival in Patients With Surgically Resected Pancreatic Neuroendocrine Tumors.
Rachel E Rosenblum, Cynthia Harris, K. Baeg, J. Starr +10 more
2020Pancreas13 citations
Semantic Scholar
Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome
Joseph S. Dillon, M. Kulke, D. Hörsch, L. Anthony +9 more
2020Journal of Gastrointestinal Cancer12 citations Open access
Semantic Scholar
Unbiased Assessment of H-STS cells as high-fidelity models for gastro-enteropancreatic neuroendocrine tumor drug mechanism of action analysis
Mariano J. Alvarez, P. Yan, M. Alpaugh, M. Bowden +17 more
2019bioRxiv12 citations Open access
Semantic Scholar
Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT‐3 and RADIANT‐4 trials
N. Fazio, C. Carnaghi, R. Buzzoni, J. Valle +6 more
2021Cancer11 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

L. Brais×14
Invite
L. Brais — researcher profile on SciRah
J. Strosberg×10
Invite
J. Strosberg — researcher profile on SciRah
M. Pavel×10
Invite
M. Pavel — researcher profile on SciRah
P. Kunz×9
Invite
P. Kunz — researcher profile on SciRah

×8

Invite

E. Wolin — researcher profile on SciRah

Invite

J. Chan — researcher profile on SciRah

James C. Yao×8

Invite

James C. Yao — researcher profile on SciRah

Invite

B. Wolpin — researcher profile on SciRah

Invite

K. Ng — researcher profile on SciRah

Invite

J. Valle — researcher profile on SciRah

Invite

N. Fazio — researcher profile on SciRah

Invite

C. Fuchs — researcher profile on SciRah